Equities analysts forecast that Agilent Technologies, Inc. (NYSE:A) will announce earnings of $0.91 per share for the current fiscal quarter, Zacks Investment Research reports. Six analysts have provided estimates for Agilent Technologies’ earnings, with estimates ranging from $0.87 to $0.93. Agilent Technologies reported earnings of $0.71 per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 28.2%. The firm is expected to report its next quarterly earnings report on Thursday, May 20th.
On average, analysts expect that Agilent Technologies will report full-year earnings of $3.87 per share for the current financial year, with EPS estimates ranging from $3.83 to $3.91. For the next fiscal year, analysts anticipate that the company will post earnings of $4.33 per share, with EPS estimates ranging from $4.20 to $4.45. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Agilent Technologies.
Agilent Technologies (NYSE:A) last announced its quarterly earnings results on Monday, February 15th. The medical research company reported $1.06 earnings per share for the quarter, beating analysts’ consensus estimates of $0.89 by $0.17. Agilent Technologies had a net margin of 13.47% and a return on equity of 21.02%. The business had revenue of $1.55 billion during the quarter, compared to analysts’ expectations of $1.43 billion. During the same period last year, the business earned $0.81 earnings per share.
A number of brokerages recently weighed in on A. Bank of America upgraded shares of Agilent Technologies from a “neutral” rating to a “buy” rating and set a $147.00 price objective for the company in a report on Wednesday, February 17th. Canaccord Genuity lifted their price objective on shares of Agilent Technologies from $80.00 to $85.00 and gave the company a “hold” rating in a report on Monday. SVB Leerink lifted their price objective on shares of Agilent Technologies from $130.00 to $140.00 and gave the company an “outperform” rating in a report on Wednesday, February 17th. Citigroup upgraded shares of Agilent Technologies from a “neutral” rating to a “buy” rating and set a $150.00 price target for the company in a research note on Thursday, March 18th. Finally, KeyCorp lifted their price target on shares of Agilent Technologies from $130.00 to $148.00 in a research note on Wednesday, February 17th. Seven investment analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $108.03.
Shares of A opened at $133.19 on Friday. Agilent Technologies has a 1-year low of $73.42 and a 1-year high of $137.83. The stock has a market cap of $40.58 billion, a PE ratio of 57.91, a P/E/G ratio of 3.82 and a beta of 1.04. The firm has a 50-day simple moving average of $129.46 and a two-hundred day simple moving average of $120.67. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.33 and a quick ratio of 1.84.
The company also recently disclosed a quarterly dividend, which was paid on Wednesday, April 28th. Shareholders of record on Tuesday, April 6th were paid a $0.194 dividend. The ex-dividend date of this dividend was Monday, April 5th. This represents a $0.78 annualized dividend and a yield of 0.58%. Agilent Technologies’s dividend payout ratio is currently 23.78%.
Agilent Technologies declared that its Board of Directors has initiated a stock repurchase plan on Tuesday, February 16th that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the medical research company to repurchase up to 5% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s board believes its stock is undervalued.
In other news, CEO Michael R. Mcmullen sold 15,095 shares of the company’s stock in a transaction on Thursday, April 8th. The shares were sold at an average price of $130.26, for a total transaction of $1,966,274.70. Following the transaction, the chief executive officer now directly owns 279,124 shares of the company’s stock, valued at approximately $36,358,692.24. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Samraat S. Raha sold 1,000 shares of the company’s stock in a transaction on Wednesday, March 31st. The stock was sold at an average price of $127.50, for a total transaction of $127,500.00. Insiders sold a total of 34,614 shares of company stock worth $4,572,425 over the last three months.
Several institutional investors have recently added to or reduced their stakes in the stock. Ellevest Inc. boosted its position in shares of Agilent Technologies by 5.9% in the 1st quarter. Ellevest Inc. now owns 2,434 shares of the medical research company’s stock worth $309,000 after buying an additional 135 shares in the last quarter. Mastrapasqua Asset Management Inc. boosted its position in shares of Agilent Technologies by 8.2% in the 1st quarter. Mastrapasqua Asset Management Inc. now owns 34,300 shares of the medical research company’s stock worth $4,361,000 after buying an additional 2,587 shares in the last quarter. State of Michigan Retirement System boosted its position in shares of Agilent Technologies by 192.9% in the 1st quarter. State of Michigan Retirement System now owns 230,206 shares of the medical research company’s stock worth $29,268,000 after buying an additional 151,600 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Agilent Technologies by 4.4% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 231,563 shares of the medical research company’s stock worth $29,441,000 after buying an additional 9,743 shares in the last quarter. Finally, Raymond James Trust N.A. boosted its position in shares of Agilent Technologies by 9.9% in the 1st quarter. Raymond James Trust N.A. now owns 4,074 shares of the medical research company’s stock worth $518,000 after buying an additional 367 shares in the last quarter.
About Agilent Technologies
Agilent Technologies, Inc engages in the provision of application focused solutions for life sciences, diagnostics and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that enable to identify, quantify and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level.
Read More: Why do companies pay special dividends?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.